A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20mg), Multi-National, Multicentre Study of Weight-Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20mg), Multi-National, Multicentre Study of Weight-Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms RIO-ASIA
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2008 Actual number of patients are 643 as reported by ClinicalTrials.gov.
    • 07 Jul 2008 Actual completion date for this trial Apr 2007 is added as reported by ClinicalTrials.gov.
    • 02 Aug 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top